araag2/HINT huggingface dataset:
Clinical trial NCT00244426 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: indobufen, aspirin
SMILES: CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic or paroxysmal non rheumatic atrial fibrillation with cardioembolic risk
             factors: hypertension, ischemic cardiopathy, Congestive Heart Failure, diabetes
             mellitus

        Exclusion Criteria:

          -  Clinically relevant organ disease

          -  creatinine clearance < 30 ml/min

          -  gastric or duodenal ulcer

          -  severe anaemia or poliglobulia
Clinical trial NCT01530620 (phase 3, status: completed)
Conditions: neurogenic urinary bladder disorder, urinary bladder, neurogenic, bladder disorder, neurogenic, urinary bladder disorder, neurogenic, neurogenic bladder disorder, urinary bladder neurogenic dysfunction, urologic diseases, overactive detrusor function, urinary incontinence
ICD codes: G98.0, K59.2, M48.061, M48.062, N39.492, R32, R39.81, N39.498, L24.A2
Drugs: propiverine hydrochloride er (extended release), propiverine hydrochloride ir (immediate release)
SMILES: CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1, CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Caucasian patients aged ≥18 and ≤70 years

          -  Voluntarily signed informed consent

          -  Neurogenic detrusor overactivity with occurrence of reflex detrusor contractions

          -  Reflex volume of ≤250 mL

          -  Intact reflex arcs in the area of segments S2-S4

        Exclusion Criteria:

          -  Patients suffering from multiple sclerosis under unstable conditions

          -  Augmented reflex bladder

          -  Patients with increased residual urine (≥20 % of the maximum bladder capacity), in
             whom catheterization is not possible

          -  Acute urinary tract infection

          -  Electrostimulation therapy (within 4 weeks propir to Visit 1)

          -  Anomalies of the lower genitourinary tract (e.g. ectopic ureters, fistulas, urethral
             stenosis)

          -  Radiation bladder, interstitial cystitis, bladder calculi, bladder carcinoma

          -  Surgery of the lower genitourinary tract within the last 6 months (e.g. prostatectomy,
             hysterectomy, tumor surgery)

          -  Pre-existing medical contraindications for anticholinergics

          -  Cardiac insufficiency (NYHA stage III/ IV)

          -  Therapy with botulinum toxin within the last 12 months

          -  Evidence of severe renal, hepatic or metabolic disorders

          -  History of drug or alcohol abuse

          -  Concomitant medication known to have a potential to interfere with the trial
             medication

          -  Known hypersensitivity to Propiverine hydrochloride or excipients contained in the
             trial medication, respectively

          -  Pregnant or breast-feeding women, or women of childbearing potential without using any
             reliable contraceptive method

          -  Patients with impaired co-operation or who are unable to understand the nature, scope
             and possible consequences of the study
Clinical trial NCT00287729 (phase 3, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: pirfenidone, placebo
SMILES: CC1=CN(C(=O)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Primary Inclusion criteria:

          -  diagnosis of idiopathic pulmonary fibrosis

          -  40 to 80 years of age

          -  Forced Vital Capacity ≥ 50% predicted value

          -  carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value

          -  either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90%
             predicted value

          -  no improvement in past year

          -  able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more
             than 6 liters per minute supplemental oxygen

        Primary Exclusion criteria:

          -  unable to undergo pulmonary function testing

          -  evidence of significant obstructive lung disease or airway hyper-responsiveness

          -  in the clinical opinion of the investigator, the patient is expected to need and be
             eligible for a lung transplant within 72 weeks of randomization

          -  active infection

          -  liver disease

          -  cancer or other medical condition likely to result in death within 2 years

          -  diabetes

          -  pregnancy or lactation

          -  substance abuse

          -  personal or family history of long QT syndrome

          -  other IPF treatment

          -  unable to take study medication

          -  withdrawal from other IPF trials
Clinical trial NCT01066962 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: darunavir/ritonavir qd + raltegravir bid, darunavir/r qd + tenofovir/emtricitabine qd (fixed dose combination)
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with confirmed HIV infection

          -  Age ≥ 18 years

          -  Written informed consent

          -  Male patient or non-pregnant, non-lactating female

          -  No previous treatment with any antiretroviral drugs

          -  HIV-1 RNA > 1000 copies/ml

          -  Indication to start an antiretroviral treatment as long as subject has also a CD4 cell
             count ≤ 500/mm3 either at screening or on a sample taken within 3 months before
             screening

          -  No major IAS-USA mutations on genotypic testing at the screening visit or on any
             historical genotype, if available

        Non-inclusion Criteria:

          -  Woman without effective contraception method (recommended contraception during the
             trial is mechanical + a second method other than an oral contraceptive)

          -  Pregnant or breastfeeding woman

          -  Woman expecting to conceive during the study

          -  HIV-2 co-infection

          -  Creatinine clearance < 60 ml/mn (Cockcroft & Gault equation), alkaline phosphatase,
             ASAT, or ALAT ≥ 5 ULN

          -  Patient with significant impairment of hepatic function, defined as serum albumin <
             2.8 g/dl or INR > 1.7 or presence of ascites, in the absence of another explanation
             for the abnormal finding

          -  CD4 > 500/mm3 at screening, except in case of symptomatic HIV disease (defined by
             conditions qualifying for CDC category B or C) or CD4 ≤ 500/mm3 on a sample taken
             within 3 months before screening.

          -  Any major IAS-USA mutation conferring resistance to one or more of reverse
             transcriptase or protease inhibitors on genotypic testing at screening

          -  Mycobacteriosis under treatment

          -  Malignancy requiring chemotherapy or radiotherapy

          -  Positive HBs Ag

          -  HCV infection for which specific treatment is ongoing or planned during the first year
             on trial treatment

          -  Known hypersensitivity to one of the trial drugs or its excipients

          -  Contraindicated concomitant treatment

          -  Anticipated non-compliance with the protocol

          -  Participation in another clinical trial with an on-going exclusion period at screening

          -  Subject under legal guardianship or incapacitation

          -  Subject, who in the opinion of the investigator, is unable to complete the study
             period
Clinical trial NCT00432679 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rosiglitazone (brl49653c)
SMILES: CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
Eligibility criteria:

        Inclusion criteria:

          -  Patients with type 2 diabetes mellitus managed by SU will be candidate for this study.
             These candidates will be checked up on their clinical laboratory data, and must have
             adequate blood, liver and kidney function.

        Exclusion criteria:

          -  Patient with serious cardiovascular disease or serious hepatic disease will not be
             eligible.
Clinical trial NCT00003824 (phase 3, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: cephalexin, ciprofloxacin
SMILES: CC1=NC=C(N1CCO)[N+]([O-])=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
Reason stopped: 
    permanently closed due to poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Stage Ta (any grade) transitional cell carcinoma of the bladder on
        basis of cystoscopy Recurrent disease no greater than T1 Must not be at high risk for upper
        tract (ureter or renal pelvic) transitional cell cancers

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Not pregnant or nursing Fertile patients must use effective contraception No other prior
        malignancy in the past 5 years except adequately treated basal cell or squamous cell skin
        cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in
        complete remission No allergies to fluoroquinolones If allergic to penicillin or
        cephalosporin, must be able to take co-trimoxazole

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 28 days
        since prior intravesical therapy and recovered Endocrine therapy: Not specified
        Radiotherapy: At least 28 days since prior radiotherapy and recovered Surgery: Not
        specified Other: At least 3 months prior to cystoscopy since prior fluoroquinolones No
        concurrent fluoroquinolones No concurrent hemodialysis or peritoneal dialysis No concurrent
        probenecid or theophylline No concurrent antacids containing aluminum, magnesium or
        calcium, products containing iron or zinc, caffeine, cyclosporine, or warfarin
Clinical trial NCT00363909 (phase 3, status: completed)
Conditions: breast cancer, hot flashes, psychosocial effects of cancer and its treatment
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: citalopram hydrobromide
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Must meet 1 of the following criteria:

               -  History of breast cancer

                    -  No current malignant disease

               -  No history of breast cancer and refused estrogen replacement therapy due to
                  perceived increased risk of breast cancer

          -  Bothersome hot flashes, defined as hot flashes ≥ 14 times/week and of sufficient
             severity to make the patient desire therapeutic intervention

          -  Presence of hot flashes ≥ 1 month prior to study entry

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal, as defined by 1 of the following criteria:

               -  Absence of a menstrual period in the past 12 months

               -  Bilateral oophorectomy

               -  Absence of a menstrual period in the past 6 months with follicle-stimulating
                  hormone (FSH) level > 40 mIU/mL

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 6 months

          -  Willing to provide blood samples during study participation

          -  No history of allergic or other adverse reactions to citalopram hydrobromide or other
             selective serotonin reuptake inhibitors (SSRIs)

          -  No documented mania or hypomania

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior and no concurrent antineoplastic chemotherapy

          -  At least 4 weeks since prior and no concurrent androgens, estrogens, or progestational
             agents

          -  At least 3 months since prior antidepressant use, including Hypericum perforatum (St.
             John's wort)

          -  Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed if on a constant
             dose for ≥ 4 weeks and continuing medication during study period

          -  No other concurrent or planned agents for treating hot flashes (e.g., phenobarbital,
             megestrol, or clonidine)

               -  Stable dose of vitamin E allowed as long as it was started > 30 days prior to
                  study entry

          -  Concurrent soy allowed

          -  Concurrent gabapentin allowed for reasons other than hot flashes if on a constant dose
             for ≥ 1 month and continuing during study period
Clinical trial NCT00654381 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bi 1356, bi 1356, voglibose placebo, bi 1356 placebo, voglibose
SMILES: CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Eligibility criteria:

        Inclusion criteria:

          1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy
             has to be stable for at least 10 weeks before Visit 1.

          2. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at Visit 3 (beginning of the 2-week
             placebo run-in phase)

          3. Age: >= 20 and <= 80

          4. Body Mass Index (BMI) <= 40 kg/m2

        Exclusion criteria:

          1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months
             before Visit 1

          2. Impaired hepatic function

          3. History of severe allergy/hypersensitivity

          4. Treatment with anti-diabetic, anti obesity drugs, etc 3 months before Visit 1

          5. Fasting blood glucose >240 mg/dl (=13.3 mmol/L) at Visits 2 or 3
Clinical trial NCT00281320 (phase 3, status: completed)
Conditions: psychosis
ICD codes: F53.1, F29
Drugs: asenapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Elderly subjects with psychosis

        Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant

        medical condition.

          -  Have an established diagnosis of dementia
Clinical trial NCT00398983 (phase 2/phase 3, status: completed)
Conditions: acute myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients (greater than 18 years) with acute myelogenous leukemia (AML) by World
             Health Organization (WHO) criteria (greater than 20% blasts) and unfavorable risk
             cytogenetics (including intermediate and poor risk categories) in first CR or complete
             remission without full platelet recovery (CRp)

          -  Adult patients (greater than 18 years) in second or subsequent Complete Response (CR)
             (or CRp)

          -  Patients in first CR (or CRp) may have received any induction chemotherapy regimen;
             they may have received post-remission consolidation therapy (except for transplant)
             prior to inclusion in this protocol

          -  Patients in 2nd or subsequent CR (or CRp) may have received any appropriate salvage
             regimen before achieving CR and may have received further therapy before inclusion

          -  Performance status of 0, 1, or 2

          -  Adequate organ function with creatinine less than or equal to 2.0 mg/dL, bilirubin
             less than or equal to 3.5 mg/dL and aspartate aminotransferase (AST or SGOT) and
             alanine aminotransferase (ALT or SGPT) less than or equal to 3 times institutional
             upper limit of normal

        Exclusion Criteria:

          -  Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative
             pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous
             surgical sterilization

          -  Known to be HIV+

          -  Active and uncontrolled disease/infection as judged by the treating physician

          -  Unable or unwilling to sign the consent form

          -  No other investigational therapy within the past 14 days
Clinical trial NCT00699517 (phase 3, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: ombrabulin (ave8062), placebo
SMILES: COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1NC(=O)[C@@H](N)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Histologically proven soft tissue sarcoma

          -  Unresectable locoregional recurrent or metastatic soft tissue sarcoma

          -  Failure of a previous anthracycline-based regimen administered recommended dose and of
             prior ifosfamide therapy

        Exclusion criteria:

          -  Less than 3 weeks elapsed from prior treatment with radiotherapy, surgery, or
             chemotherapy to the time of randomization

          -  Brain metastases and carcinomatous leptomeningitis

          -  Uncontrolled hypertension

          -  Known platinum hypersensitivity

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00082433 (phase 3, status: completed)
Conditions: cancer, breast cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ixabepilone + capecitabine, capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        -  Patients must have received prior treatment which included both an anthracycline
             (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).

          -  Patients must have received no more than two prior chemotherapy regimens. Patients who
             have not received treatment for metastatic disease must have relapsed within one year.

          -  Patients may not have any history of brain and/or leptomeningeal metastases.

          -  Patients may not have Grade 2 or worse neuropathy at the time of study entry.

          -  Patients may not have had prior treatment with any epothilones and/or capecitabine
             (i.e. Xeloda)
Clinical trial NCT00717457 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, taspoglutide, taspoglutide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  type 2 diabetes receiving metformin and/or pioglitazone or rosiglitazone for at least
             12 weeks;

          -  HbA1c >=7.0% and <=10% at screening;

          -  BMI >=25kg/m2 (>23kg/m2 for Asians) and <=45kg/m2 at screening;

          -  stable weight +/- 5% for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  history of type 1 diabetes, diabetes resulting from pancreatic injury or secondary
             forms of diabetes;

          -  history of acute metabolic diabetic complications within the previous 6 months;

          -  evidence of clinically significant diabetic complications;

          -  known proliferative diabetic retinopathy;

          -  myocardial infarction (MI), coronary artery bypass surgery, post-transplantation
             cardiomyopathy (PTCM) or stroke within the past 6 months;

          -  any abnormality in clinical laboratory test or ECG, which precludes safe involvement
             in the study as judged by the investigator;

          -  known hemoglobinopathy or chronic anemia;

          -  clinically significant gastrointestinal disease.